Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV Positive~* On HAART, with plasma viral load \< 50 copies/ml for previous 12 months or more~* Able to provide informed consent~* HAND diagnosis, with symptom progression within previous 6 months~Exclusion Criteria:~* Non-HIV related neurological disorders and active central nervous system (CNS) opportunistic infection (as assessed by full blood count, electrolytes, creatinine, glucose, liver funciton tests, cryptococcal antigen, venereal disease research laboratory (VDRL), MRI brain scan and CSF analysis for cell count, protein, glucose, culture, VDRL and cryptococcal antigen)~* Psychiatric disorders on the psychiatric axis~* Current major depression~* Current substance use disorder, or severe substance use disorder within 12 months of study entry~* Active Hepatitis C Virus (HCV) (detectable HCV RNA)~* History of loss of consciousness \> 1 hour~* Non-proficient in English~* Medications known to pharmacologically interact with antiretrovirals (ARVs)~* Currently taking an entry inhibitor~* Pregnancy (as assessed by the urine pregnancy test)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care HAART regimen (Type: NO_INTERVENTION): Participants randomised to this arm of the trial will remain on their usual prescribed HAART regimen.
- Maraviroc (Type: EXPERIMENTAL): Participants randomised to this arm will remain on their usual prescribed HAART regimen, with the addition of Maraviroc. Maraviroc will be prescribed according to the Product Information Sheet, with consideration given to background therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).